Read More Analyst Ratings News Price Target Needham Maintains Buy on Nutanix, Raises Price Target to $31 By Benzinga Newsdesk October 17, 6:19 AM Needham analyst Mike Cikos maintains Nutanix (NASDAQ:NTNX) with a Buy and raises the price target from $25 to $31. NTNX
Read More Biotech General Health Care News Novocure Has Enrolled The Final Patient In The Pivotal METIS Study Evaluating The Efficacy Of Tumor Treating Fields (TT Fields) Therapy Following Stereotactic Radiosurgery For Brain Metastases Resulting From Non-small Cell Lung Cancer By Benzinga Newsdesk March 1, 8:09 AM Following the completion of enrollment, patients will be followed for a minimum of 12 months. NVCR
Read More Analyst Ratings News Price Target BMO Capital Maintains Outperform on Sibanye Stillwater, Raises Price Target to $25 By Benzinga Newsdesk March 7, 9:59 AM BMO Capital analyst Raj Ray maintains Sibanye Stillwater (NYSE:SBSW) with a Outperform and raises the price target from $22 to $25. SBSW
Read More Analyst Color Analyst Ratings News Price Target Upgrades Wix.com’s New Business, Pricing Power Likely To Contribute To FCF, Analyst Says By Anusuya Lahiri January 12, 1:31 PM RBC Capital analyst Brad Erickson upgraded Wix.com Ltd (NASDAQ:WIX) from Sector Perform to Outperform and raised the price target from $80 to… WIX